» Articles » PMID: 28785242

Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth

Overview
Specialty Endocrinology
Date 2017 Aug 9
PMID 28785242
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Activating transcription factor-5 (ATF5) is an anti-apoptotic factor and has been implicated in enhancing the survival of cancer cells under stress and in regulating the autophagy process. Targeting ATF5 in anticancer therapy may be particularly attractive because of its differential role in cancer cells than in non-transformed cells, thus allowing specificity of the treatment. Using the delivery of short hairpin RNA vectors into the Mvt1 and Met1 cell lines, we tested the role of ATF5 in the development of mammary tumors and in regulating proliferation and migration of these cells . In this study, we demonstrate that knockdown of ATF5 (ATF5-KD) in both cell lines results in a decreased tumor volume and weight, as well as in a reduced proliferation rate and migratory potential of the cells. In addition, ATF5-KD led to an increased autophagy flux and a shift in the sub-populations comprising Mvt1 cells from the aggressive CD24-positive cells toward less aggressive CD24-negative cells. Taken together, these findings suggest that ATF5 plays an important role in enhancing mammary tumor cells overall aggressiveness and in promoting mammary tumor growth and emphasize the possible benefit of anti-ATF5 therapy in breast cancer patients, particularly, against tumors characterized with the positive expression of cell surface CD24.

Citing Articles

Activating Transcription Factor 5 Promotes Tumorigenic Capability in Cervical Cancer Through the Wnt/β-Catenin Signaling Pathway.

Shi F, Wei Y, Huang Y, Yao D Cancer Manag Res. 2025; 17:131-143.

PMID: 39881945 PMC: 11775824. DOI: 10.2147/CMAR.S496925.


A bioinformatic analysis found low expression and clinical significance of ATF4 in breast cancer.

Shao L, Zhu Z, Jia X, Ma Y, Dong C Heliyon. 2024; 10(2):e24669.

PMID: 38312639 PMC: 10835298. DOI: 10.1016/j.heliyon.2024.e24669.


Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers.

Greene L, Zhou Q, Siegelin M, Angelastro J Cells. 2023; 12(4).

PMID: 36831248 PMC: 9954556. DOI: 10.3390/cells12040581.


Advancements in Activating Transcription Factor 5 Function in Regulating Cell Stress and Survival.

Paerhati P, Liu J, Jin Z, Jakos T, Zhu S, Qian L Int J Mol Sci. 2022; 23(13).

PMID: 35806136 PMC: 9266924. DOI: 10.3390/ijms23137129.


TMEM176B Regulates AKT/mTOR Signaling and Tumor Growth in Triple-Negative Breast Cancer.

Kang C, Rostoker R, Ben-Shumel S, Rashed R, Duty J, Demircioglu D Cells. 2021; 10(12).

PMID: 34943938 PMC: 8700203. DOI: 10.3390/cells10123430.


References
1.
Persengiev S, Green M . The role of ATF/CREB family members in cell growth, survival and apoptosis. Apoptosis. 2003; 8(3):225-8. DOI: 10.1023/a:1023633704132. View

2.
Runz S, Mierke C, Joumaa S, Behrens J, Fabry B, Altevogt P . CD24 induces localization of beta1 integrin to lipid raft domains. Biochem Biophys Res Commun. 2007; 365(1):35-41. DOI: 10.1016/j.bbrc.2007.10.139. View

3.
Monaco S, Angelastro J, Szabolcs M, Greene L . The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer. 2007; 120(9):1883-90. DOI: 10.1002/ijc.22469. View

4.
Zelenko Z, Gallagher E, Tobin-Hess A, Belardi V, Rostoker R, Blank J . Silencing vimentin expression decreases pulmonary metastases in a pre-diabetic mouse model of mammary tumor progression. Oncogene. 2016; 36(10):1394-1403. PMC: 5332535. DOI: 10.1038/onc.2016.305. View

5.
Ishihara S, Yasuda M, Ishizu A, Ishikawa M, Shirato H, Haga H . Activating transcription factor 5 enhances radioresistance and malignancy in cancer cells. Oncotarget. 2015; 6(7):4602-14. PMC: 4467102. DOI: 10.18632/oncotarget.2912. View